Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
3.230
-0.090 (-2.71%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Pyxis Oncology Revenue
Pyxis Oncology had revenue of $11.04M in the twelve months ending June 30, 2026, up 291.42% year-over-year. In the year 2025, Pyxis Oncology had annual revenue of $13.86M, down -14.17%.
Revenue (ttm)
$11.04M
Revenue Growth
+291.42%
P/S Ratio
24.41
Revenue / Employee
$197,107
Employees
56
Market Cap
269.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.86M | -2.29M | -14.17% |
| Dec 31, 2024 | 16.15M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Niagen Bioscience | 129.08M |
| AC Immune | 21.67M |
| Alector | 13.86M |
| Surrozen | 11.51M |
| Whitehawk Therapeutics | 7.15M |
| Camp4 Therapeutics | 4.22M |
PYXS News
- 10 days ago - Pyxis Oncology files to sell 39.2M shares of common stock for holders - TheFly
- 10 days ago - Pyxis Oncology Registration statement: Registration filing - Filings
- 14 days ago - Pyxis Oncology reports Q2 EPS (40c), consensus (35c) - TheFly
- 17 days ago - Pyxis Oncology Slides: Corporate presentation - Filings
- 17 days ago - Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - GlobeNewsWire
- 17 days ago - Pyxis Oncology Quarterly report: Q2 2026 - Filings
- 17 days ago - Pyxis Oncology Earnings release: Q2 2026 - Filings
- 4 weeks ago - Pyxis Oncology initiated with an Overweight at Wells Fargo - TheFly